Format

Send to:

Choose Destination
See comment in PubMed Commons below
Gut Liver. 2014 Jan;8(1):109-12. doi: 10.5009/gnl.2014.8.1.109. Epub 2014 Jan 13.

Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.

Author information

  • 1Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 2Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 3Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.

KEYWORDS:

Gemcitabine; Hemolytic-uremic syndrome; Pancreatic neoplasms

PMID:
24516709
[PubMed - indexed for MEDLINE]
PMCID:
PMC3916680
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Inforang Icon for PubMed Central
    Loading ...
    Write to the Help Desk